Cargando…

Valorising and Creating Access to Innovative Medicines in the European Union

This Perspective describes (a) the current situation, (b) challenges and initiatives, (c) and formulates recommendations to valorize and create access to innovative medicines in the EU. We are currently still far away from optimal assessment of value for money in the EU. On the one hand, valorizing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Annemans, Lieven, Cleemput, Irina, Hulstaert, Frank, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190181/ https://www.ncbi.nlm.nih.gov/pubmed/22013421 http://dx.doi.org/10.3389/fphar.2011.00057

Ejemplares similares

The challenges of access to innovative medicines with limited evidence in the European Union
por: Vallano, Antonio, et al.
Publicado: (2023)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

How to Assess the Value of Medicines?
por: Simoens, Steven
Publicado: (2010)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

Access to medicines for rare diseases: A European regulatory roadmap for academia
por: Rosenberg, Noa, et al.
Publicado: (2023)

Valorisation of Wasted Immature Tomato to Innovative Fermented Functional Foods
por: Pereira, Nelson, et al.
Publicado: (2023)

Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
por: Gozzo, Lucia, et al.
Publicado: (2022)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
por: Nuijten, Mark J. C., et al.
Publicado: (2015)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2021)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Affordability of medicines in the European Union
por: Zaprutko, Tomasz, et al.
Publicado: (2017)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications
por: Incze, András, et al.
Publicado: (2022)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Where is the ‘global’ in the European Union’s Health Research and Innovation Agenda?
por: Berner-Rodoreda, Astrid, et al.
Publicado: (2019)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Not one, but many: developing a multi-indication pricing model for medicines in Belgium
por: Maes, Ingrid, et al.
Publicado: (2023)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

European Union ban on Ayurvedic Medicines
por: Patwardhan, Bhushan
Publicado: (2011)

Waste Management: Valorisation Is the Way
por: Gemar, German, et al.
Publicado: (2021)

New pricing models for generic medicines to ensure long-term sustainable competition in Europe
por: Francois, Clement, et al.
Publicado: (2023)

Cost-effectiveness of exercise referral schemes: a systematic review of health economic studies
por: Werbrouck, Amber, et al.
Publicado: (2021)

Spices and Seasoning Mixes in European Union—Innovations and Ensuring Safety
por: Śmiechowska, Maria, et al.
Publicado: (2021)

Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review
por: Perehudoff, Katrina, et al.
Publicado: (2021)

Guidance for Demonstrating the Societal Value of new Antibiotics
por: Simoens, Steven, et al.
Publicado: (2021)

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
por: van Overbeeke, Eline, et al.
Publicado: (2019)

Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China
por: Liu, Peng, et al.
Publicado: (2021)

Responsible decision-making for plant research and breeding innovations in the European Union
por: Eriksson, Dennis, et al.
Publicado: (2017)

Public Health Policies in European Union: An Innovation Strategy—Horizon 2020
por: Soulis, Sotiris, et al.
Publicado: (2015)

Valorisation of face mask waste in mortar
por: Ajam, Lassaad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tj05ukifh7t4mb5en2vqc2g0j3